The reception concluded with conversations and discussions over drinks and food.
NPF Research Reception at SID
For the first time since 2019, the National Psoriasis Foundation hosted an in-person reception at the 2022 Society for Investigative Dermatology Annual Meeting in Portland, OR.
The reception allowed researchers to interact with NPF leadership and research staff, see posters presenting results from NPF-funded research, and hear updates from NPF-funded research projects and internal NPF research initiatives.
Program highlights included:
Joel M. Gelfand, M.D., MSCE provided an update on the “Cardiovascular Disease (CVD) Prevention for Psoriasis and Psoriatic Arthritis [CP3]” study, funded through the NPF Psoriasis Prevention Initiative. This multi-disciplinary, multi-institutional study aims to explore the feasibility and effectiveness of a care coordination model for lowering risk of cardiovascular disease in patients with psoriatic disease. Results from a survey of patients and clinicians suggest patients and clinicians perceive engaging a specialist-led model of care to improve CVD prevention positively.
Sergei Koralov, Ph.D. presented an update on research conducted in collaboration with Jose Scher, M.D. and his lab at New York University School of Medicine through the NPF Psoriatic Arthritis Diagnostic Test Grant. This research utilizes expanded Cellular Indexing of Transcriptomes and Epitopes by sequencing (exCITE-seq) to further understanding of changes in systemic immune responses resulting from the progression from psoriasis to psoriatic arthritis.
.jpg?ixlib=gatsbyFP&auto=compress%2Cformat&fit=max&rect=0%2C0%2C640%2C640&w=99&h=99){kind=icon}
Jeffery B. Cheng, M.D., Ph.D., recipient of an NPF Discovery Grant, presented research on the development of the RashX tool enabling clinicians to learn more about classification of rashes. Results from this exciting work were recently published in Science Immunology.
George C. Gondo, M.A., Associate Director of Research at the NPF, provided an update of ongoing efforts at the NPF address health disparities in the psoriatic disease community.
Wilson Liao, MD, presented work conducted in collaboration with the NPF to define remission and cure for psoriasis and psoriatic arthritis, develop a database to create infrastructure to study difficult to treat cases of psoriasis, and the NIH Accelerating Medicines Partnership for Autoimmune and Immune-Mediated Diseases (AMP AIM).
Jennifer Fagerstrom, Chief Revenue Officer at the NPF, provided a personal story about the impact research on psoriatic disease has on the lives of patients.
